Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 1;35(6):513-521.
doi: 10.1097/CCO.0000000000000984. Epub 2023 Jul 24.

Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls

Kristin Wright  1 , Abhenil Mittal  2 , Bishal Gyawali  1   3   4
Affiliations

Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls

Kristin Wright et al. Curr Opin Oncol. .

Abstract

Purpose of review: Health technology assessment (HTA) of cancer drugs is important to identify whether drugs should be publicly funded. With increasing use of surrogate end points in clinical trials including breast cancer, a review of literature was done to synthesize evidence for validation of these surrogate end points and their potential role in HTA decisions pertaining to breast cancer.

Findings: Disease free survival (DFS) in human epidermal receptor 2 (HER2) positive early breast cancer remains the only validated surrogate end point. Other surrogate end points like pathological complete response (pCR) and event free survival (EFS) in early breast cancer (EBC) and objective response rate (ORR) and progression free survival (PFS) in advanced disease have not been validated for overall survival (OS). Moreover, surrogate end points for quality of life (QOL) have not been established and drugs that improve PFS can have detrimental effect on QOL. End points like pCR have excellent prognostic utility in individual patients but have weak correlation with survival at trial level.

Summary: Most surrogate end points used in breast cancer do not predict OS or QOL which makes it challenging to use them for decisions regarding public funding of cancer drugs. These findings are relevant to HTA agencies prior to making drug reimbursement decisions.

Keywords: breast cancer; health technology assessment; review; surrogate end points.

PubMed Disclaimer

References

    1. Hong R, Xu B. Breast cancer: an up-to-date review and future perspectives. Cancer Commun 2022; 42:913–936.
    1. Hirschfeld S, Pazdur R. Oncology drug development: United States Food and Drug Administration perspective. Crit Rev Oncol Hematol 2002; 42:137–143.
    1. Jenei K, Raymakers AJN, Bayle A, et al. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. Lancet Oncol 2023; 24:624–635.
    1. Del Paggio JC, Berry JS, Hopman WM, et al. Evolution of the randomized clinical trial in the era of precision oncology. JAMA Oncol 2021; 7:728–734.
    1. Chen EY, Haslam A, Prasad V. FDA acceptance of surrogate end points for cancer drug approval: 1992–2019. JAMA Internal Med 2020; 180:912–914.